This evaluative process is essential to lay the groundwork for testing mechanism-based therapeutic strategies to thwart resistance and improve clinical outcomes for patients with KRAS G12C–driven NSCLC and potentially other KRAS-driven tumor types. Here, KRAS is linked to non-small cell lung carcinoma.